These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38580952)

  • 1. Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre.
    Almahmoud R; Hussein A; Khaja FA; Soliman AF; Dewedar H; Shareef ZA; Mathai S
    BMC Pediatr; 2024 Apr; 24(1):244. PubMed ID: 38580952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
    Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
    Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD).
    Yassin MA; Soliman AT; De Sanctis V; Abdula MAJ; Riaz LM; Ghori FF; Yousaf A; Nashwan AJ; Abusamaan S; Moustafa A; Kohla S; Soliman DS
    Acta Biomed; 2018 Feb; 89(2-S):33-40. PubMed ID: 29451227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT; Yassin MA; De Sanctis V
    Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications.
    Kanbour I; Chandra P; Soliman A; De Sanctis V; Nashwan A; Abusamaan S; Moustafa A; Yassin MA
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018062. PubMed ID: 30416694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
    Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
    Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrinal Complications in Children and Adolescents with Thalassemia Major in Central India: An Observational Study.
    Dixit N; Shaw CK; Varshney GA; Kumar R; Saini PA; Verma P
    Indian J Pediatr; 2022 Oct; 89(10):983-988. PubMed ID: 34480715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrinopathies in beta thalassemia: a narrative review.
    Venou TM; Barmpageorgopoulou F; Peppa M; Vlachaki E
    Hormones (Athens); 2024 Jun; 23(2):205-216. PubMed ID: 38103163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment and complications of thalassemia major in Guangxi, Southern China.
    Yin XL; Wu ZK; He YY; Zhou TH; Zhou YL; Zhang XH
    Pediatr Blood Cancer; 2011 Dec; 57(7):1174-8. PubMed ID: 21394896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
    Sharma R; Seth A; Chandra J; Gohain S; Kapoor S; Singh P; Pemde H
    Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
    Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
    Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY; Li Q; Chen JJ; Chen GF; Li CG
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha.
    Panigrahi M; Swain TR; Jena RK; Panigrahi A; Debta N
    Indian J Pharmacol; 2020; 52(3):172-178. PubMed ID: 32873999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.